share_log

賽生藥業：根據《收購守則》規則22作出的交易披露

SCICLONE PHARMA: Disclosure of Dealings under Rule 22 of the Takeovers Code

Hong Kong Stock Exchange ·  Apr 30 18:13
Summary by Futu AI
赛生药业（SCICLONE PHARMA）於2024年4月30日宣布，公司股份將透過協議安排進行私有化。根據香港《公司收購及合併守則》規則22，執行人員披露了與趙宏相關的證券交易。趙宏於2024年4月29日根據公司首次公開發售後受限股份單位計劃，獲得300,000股股份獎勵。該交易後，趙宏直接持有1,100,000股，而Convergence International Holdings Ltd.持有11,979,690股，合計持股數為13,079,690股，佔公司已發行股份的2.0802%。
赛生药业（SCICLONE PHARMA）於2024年4月30日宣布，公司股份將透過協議安排進行私有化。根據香港《公司收購及合併守則》規則22，執行人員披露了與趙宏相關的證券交易。趙宏於2024年4月29日根據公司首次公開發售後受限股份單位計劃，獲得300,000股股份獎勵。該交易後，趙宏直接持有1,100,000股，而Convergence International Holdings Ltd.持有11,979,690股，合計持股數為13,079,690股，佔公司已發行股份的2.0802%。
SCICLONE PHARMA ANNOUNCED ON APRIL 30, 2024 THAT THE COMPANY'S SHARES WILL BE PRIVATIZED BY AGREEMENT. Pursuant to Rule 22 of the Hong Kong Code of Acquisitions and Mergers, the Executive disclosed the securities transactions relating to Zhao Hong. On April 29, 2024, Zhao Hong received a 300,000 share award under the company's initial public offering of restricted stock units plan. Following the transaction, Zhao Hong directly held 1,100,000 shares and Convergence International Holdings Ltd. held 11,979,690 shares for a total holding of 13,079,690 shares, representing 2.0802% of the company's issued shares.
SCICLONE PHARMA ANNOUNCED ON APRIL 30, 2024 THAT THE COMPANY'S SHARES WILL BE PRIVATIZED BY AGREEMENT. Pursuant to Rule 22 of the Hong Kong Code of Acquisitions and Mergers, the Executive disclosed the securities transactions relating to Zhao Hong. On April 29, 2024, Zhao Hong received a 300,000 share award under the company's initial public offering of restricted stock units plan. Following the transaction, Zhao Hong directly held 1,100,000 shares and Convergence International Holdings Ltd. held 11,979,690 shares for a total holding of 13,079,690 shares, representing 2.0802% of the company's issued shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.